Oral prostacyclin enhances the pulmonary vasodilatory effect of nitric oxide in children with pulmonary hypertension

Cardiology in the Young

Volumn 7, Issue 4, 1997, Pages 362-369

  Uese, Kei Ichiro ^a   Ichida, Fukiko ^a   Tsubata, Shin Ichi ^a   Hashimoto, Ikuo ^a   Hamamichi, Yuji ^a   Fukahara, Kazuaki ^a   Murakami, Arata ^a   Miyawaki, Toshio ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Cyclic AMP; Cyclic GMP; Nitric oxide; Oral prostacyclin analogue; Pulmonary hypertension

Indexed keywords

EID: 0006379028     PISSN: 10479511     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1047951100004340     Document Type: Article

References (30)

1. Cohen RA, Vanhoutte PM. Endothelium-Dependent Hyperpolarization. Circulation 1995; 92: 3337-3349.
2. Pepke-Zaba J, Timothy W, Higenbottam A, Dinh-Xuan T, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173-1174.
3. Roberts JD Jr, Polaner DM, Lange P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992; 340: 818-819.
4. Kinsella JP, Neish SR, Ivy DD, Shaffer E, Abman SH. Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide. J Pediatr 1993; 123: 103-108.
5. Finner NN, Etches PC, Kamstra D, Tierney AJ, Peliowski A, Ryan A. Inhaled nitric oxide in infants reffered for extracorporeal membrane oxygenation: dose response. J Pediatr 1994; 124: 302-308.
6. Abman SH, Griebel JL, Parker DK, Schmidt JM, Swanton D, Kinsella JP. Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failure. J Pediatr 1994; 124: 881-888.
7. Roberts JD, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM. Inhaled nitric oxide in congenital heart disease. Circulation 1993; 87: 447-453.
8. Journois D, Pouard P, Mauriat P, Malhere T, Vouhe P, Safran D. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects. J Thorac Cardiovasc Surg 1994; 107: 1129-1135.
9. Miller OI, Clermajer DS, Deanfield JE, Macrae DJ. Very-low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart disease. J Thorac Cardiovasc Surg 1994; 108: 487-494.
10. Goldman AP, Delius RE, Deanfield JE, Macrae DJ. Nitric oxide is superior to prostacyclin for pulmonary hypertension after cardiac operations. Ann Thorac Surg 1995; 60: 300-306.
11. Day RW, Lynch JM, Shaddy RE, Orsmond GS. Pulmonary vasodilatory effects of 12 and 60 parts per million inhaled nitric oxide in children with ventricular septal defect. Am J Cardiol 1995; 75: 196-198.
12. Beghetti M, Habre W, Friedli B, Berner M. Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br Heart J 1995; 73: 65-68.
13. Berner M, Beghetti M, Spahr-Schopfer I, Oberhansli I, Friedli B. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. Am J Cardiol 1996; 77: 532-535.
14. Gamillscheg A, Zobel G, Urlesberger B, et al. Inhaled nitric oxide in patients with critical pulmonary perfusion after Fontan-type procedures and bidirectional Glenn anastomosis. J Thorac Cardiovasc Surg 1997; 113: 435-442.
15. Bush A, Busst C, Booth K, Knight WB, Shinebourne EA. Does prostacyclin enhance the selective pulmonary vasodilator effect of oxygen in children with congenital heart disease? Circulation 1986; 74: 135-144.
16. Bush A, Busst C, Knight WB, Shineborne EA. Modification of pulmonary hypertension secondary to congenital heart disease by prostacyclin therapy. Am Rev Respir Dis 1987; 136: 767-769.
17. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (Epoprostenol): Results of a randomized trial. Ann Intern Med 1990; 112: 485-491
18. Gomez-Sanchez MA, De La Calzada CS, Pajuelo CG, et al. Different hemodynamic responses between acute and chronic infusion of Iloprost (prostacyclin-stable analogue) in severe pulmonary hypertension. Am Rev Respir Dis 1991; 144:1404-1405
19. Schranz D, Zepp F, Iversen S, et al. Effects of tolazoline and prostacyclin on pulmonary hypertension in infants after cardiac surgery. Crit Care Med 1992; 20: 1243-1249
20. Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (Epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993; 70: 366-370
21. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (Prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301
22. Graham DR, Keldermans MM, Klemm LW, Semenza NJ, Shafer ML. Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters. Am J Med 1991; 91: 95S-100S.
23. Toda N. Beraprost sodium. Cardiovasc Drug Rev 1988; 6: 222-238
24. Takeo S. Pharmacodynamics and clinical studies with beraprost sodium, a drug for peripheral vascular disease. Cardiovascular Drug Reviews 1992; 10: 392-403.
25. 2 analogue, Beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996; 78: 244-247.
26. Ichida F, Tsubata S, Hashimoto I, et al. Beneficial effect of beraprost sodium, a stable analogue of prostacyclin, on pulmonary hypertension in children. Circulation 1996; 94(suppl I): I-653(abstract).
27. Katz RW, Pollack MM, Weibley RE. Pulmonary artery catheterization in pediatric intensive care. Adv Pediatr 1984; 30: 169-190.
28. LaFarge CG, Miettinen OS. The estimation of oxygen consumption. Cardiovasc Res 1970; 4: 23-30.
29. Data JL, Molony BA, Meinzinger MM, Gorman RR. Intravenous infusion of prostacyclin sodium in man: Clinical effects and influence on platelet adenosine diphosphate sensitivity and adenosine 3′ :5′ -cyclic monophosphate levels. Circulation 1981; 64: 4-12.
30. Gray DW, Marshall I. Novel signal transduction pathway mediating endotherium-dependent β adrenoceptor vasorelxation in rat thoracic aorta. Br J Pharmacol 1992; 107: 684-690.